Alcon: Pipeline, Products, Performance, Potential

Table of Contents

• Latest Results

EXECUTIVE SUMMARY

• Introduction
• Current Financial Position
  • Company Performance
  • Segment Performance
• Company Strategy
  • Key Agreements
• Product Performance Forecasts
• Pipeline Analysis
• Other Factors Affecting the Bottom Line
• Conclusions/Outlook

THERAPEUTIC AREA FOC US

R&D PIPELINE

OPHTHALMOLOGY

• Marketed Products
  • Glaucoma
    • Azopt
    • DuoTrav
    • Travatan
  • Anti-infective/Anti-inflammatory
    • Nevanac
    • Rimexel
    • TobraDex
    • Vigamox/Vegamox
  • Ocular Allergy
    • Patanol/Opatanol
  • Other
    • Retaane
• R&D Projects
• Growth Forecast

OTIC

• Marketed Products
  • Ciprodex
• R&D Projects
• Growth Forecast

APPENDIX 1 - FINANC IAL PERFORMANC E

• Full Year Results 2006

APPENDIX 2 - KEY CO RPORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

• Amgen
• Dharmacon Inc
• Eli Lilly
• Jerini AG
• Juvantia Pharma Ltd
• Kalypsys Inc
• Kyowa Hakko
• NovaCal Pharmaceuticals Inc
• Vernalis plc

APPENDIX 4 - INFRASTRUCTURE

• Research and Development Facilities
• Manufacturing Facilities

APPENDIX 5 - KEY PHARMAC EUTICAL

• SUBSIDIARIES
• Subsidiaries

APPENDIX 6 - PRODUCT INDEX

Index of Tables

• Principal Operating Results
• Sales By Business/Geographic Segment
• Operating Income By Segment
• Sales By Product Area
• Recent Product Approvals
• Major Therapeutic Areas And Sales
• Major Glaucoma Products, 2006
• Major Anti-infective/ Anti-inflammatory Products, 2006
• Major Ocular Allergy Products, 2006

Index of Charts

• Sales By Segment, 2006
• Sales By Product Area, 2006
• Glaucoma Sales (2004A-2011E)
• Anti-infect/Anti-inflammatory Sales (2004A-2011E)
• Ocular Allergy Sales (2004A-2011E)
• Otic Sales (2004A-2011E)
• Sales, Costs and Operating Income
• Profitability and Research Ratios
• R&D Expenditure and Capital Expenditure
• Current Assets, Liabilities and Ratio
• Assets, Cash and Liquidity
• Employees and Productivity